{
    "2021-01-12": [
        [
            {
                "time": "2021-06-15",
                "original_text": "Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis",
                "features": {
                    "keywords": [
                        "Beigene",
                        "Surges",
                        "Breakout",
                        "$2.2 Billion",
                        "Novartis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-15",
                "original_text": "Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene",
                "features": {
                    "keywords": [
                        "Novartis",
                        "In-Licenses",
                        "Anti-PD-1",
                        "Antibody",
                        "BeiGene"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-15",
                "original_text": "The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue",
                "features": {
                    "keywords": [
                        "Daily Biotech Pulse",
                        "GSK",
                        "Vir",
                        "COVID-19",
                        "Antibody Study",
                        "Novartis",
                        "In-Licenses",
                        "BeiGene",
                        "Cancer Drug",
                        "Earnings Preannouncements"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}